USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF ANAPHYLAXIS
The embodiments described herein include methods and formulations for treating anaphylaxis and related acute allergic reactions. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
1 . A method of reducing the duration of anaphylaxis in a patient in need thereof, comprising administering to the patient an effective amount of a combination of levocetirizine and montelukast; wherein the combination is administered at the onset of symptoms.
2 . The method of claim 1 , wherein the combination is administered in a sequential manner.
3 . The method of claim 1 , wherein the combination is administered in a substantially simultaneous manner.
4 . The method of claim 1 , further comprising the administration of an additional active agent.
5 . The method of claim 4 , wherein the additional active agent is selected from the group consisting of: a histamine H2 receptor antagonist, a beta2-agonist, oxygen, saline, a glucocorticoid, and a H1-anti-histamine.
6 . The method of claim 5 , wherein the histamine H2 antagonist is ranitidine.
7 . The method of claim 5 , wherein the histamine H2 antagonist is cimetidine.
8 . The method of claim 1 , further comprising the administration of a vasoactive agent.
9 . The method of claim 8 , wherein the vasoactive agent is epinephrine.
10 . The method of claim 8 , wherein the vasoactive agent is dopamine.
11 . The method of claim 1 , wherein the combination is administered to the patient by one or more of the routes consisting of enteral, intravenous, intraperitoneal, inhalation, intramuscular, subcutaneous and oral.
12 . The method of claim 1 , wherein the levocetirizine and montelukast are administered by the same route.